These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35299995)

  • 1. Multi-Response Based Personalized Treatment Selection with Data from Crossover Designs for Multiple Treatments.
    Kulasekera KB; Siriwardhana C
    Commun Stat Simul Comput; 2022; 51(2):554-569. PubMed ID: 35299995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Personalized Treatment Selection with Multivariate Outcome Measures in a Multiple Treatment Case.
    Siriwardhana C; Kulasekera KB
    Commun Stat Simul Comput; 2023; 52(12):5773-5787. PubMed ID: 38371330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of the optimal personalized treatment from multiple treatments with multivariate outcome measures.
    Siriwardhana C; Datta S; Kulasekera KB
    J Biopharm Stat; 2020 May; 30(3):462-480. PubMed ID: 31691633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of the optimal personalized treatment from multiple treatments with right-censored multivariate outcome measures.
    Siriwardhana C; Kulasekera KB; Datta S
    J Appl Stat; 2024; 51(5):891-912. PubMed ID: 38524800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized treatment plans with multivariate outcomes.
    Siriwardhana C; Kulasekera KB
    Biom J; 2020 Dec; 62(8):1973-1985. PubMed ID: 32627863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantiles based personalized treatment selection for multivariate outcomes and multiple treatments.
    Kulasekera KB; Siriwardhana C
    Stat Med; 2022 Jul; 41(15):2695-2710. PubMed ID: 35699385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A probability based method for selecting the optimal personalized treatment from multiple treatments.
    Siriwardhana C; Zhao M; Datta S; Kulasekera KB
    Stat Methods Med Res; 2019 Mar; 28(3):749-760. PubMed ID: 29145777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized treatment selection using data from crossover designs with carry-over effects.
    Siriwardhana C; Kulasekera KB; Datta S
    Stat Med; 2019 Dec; 38(28):5391-5412. PubMed ID: 31637762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranked set sampling in finite populations with bivariate responses: An application to an osteoporosis study.
    Azimian M; Moradi M; Jafari Jozani M; Leslie WD
    Stat Med; 2022 Apr; 41(8):1397-1420. PubMed ID: 35274755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-efficient higher-order crossover designs in comparative bioavailability studies.
    Zhou J; Yuan Y; Reynolds R; Raber S; Li Y
    Clin Pharmacokinet; 2006; 45(6):623-32. PubMed ID: 16719543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of crossover designs with nonignorable dropout.
    Wang X; Chinchilli VM
    Stat Med; 2021 Jan; 40(1):64-84. PubMed ID: 33012039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of crossover designs for longitudinal binary data with ignorable and nonignorable dropout.
    Wang X; Chinchilli VM
    Stat Methods Med Res; 2022 Jan; 31(1):119-138. PubMed ID: 34779672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An improved procedure for estimation of malignant breast cancer prevalence using partially rank ordered set samples with multiple concomitants.
    Hatefi A; Jafari Jozani M
    Stat Methods Med Res; 2017 Dec; 26(6):2552-2566. PubMed ID: 26311819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Rank Aggregation-Based Hybrid Multifilter Wrapper Feature Selection Method in Software Defect Prediction.
    Balogun AO; Basri S; Mahamad S; Capretz LF; Imam AA; Almomani MA; Adeyemo VE; Kumar G
    Comput Intell Neurosci; 2021; 2021():5069016. PubMed ID: 34868291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best linear inverse probability weighted estimation for two-phase designs and missing covariate regression.
    Wang CY; Dai J
    Stat Med; 2019 Jul; 38(15):2783-2796. PubMed ID: 30908669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal and/or efficient three treatment crossover designs for five carryover models.
    Gondaliya J; Divecha J
    J Biopharm Stat; 2020 May; 30(3):445-461. PubMed ID: 31721628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel-Haenszel method are recommended.
    Takada M; Sozu T; Sato T
    Pharm Stat; 2015; 14(3):198-204. PubMed ID: 25776032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Unified Family of Covariate-Adjusted Response-Adaptive Designs Based on Efficiency and Ethics.
    Hu J; Zhu H; Hu F
    J Am Stat Assoc; 2015 Apr; 110(509):357-367. PubMed ID: 26120220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network selection: a method for ranked lists selection.
    Cutillo L; Carissimo A; Figini S
    PLoS One; 2012; 7(8):e43678. PubMed ID: 22937075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.